{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:56:03Z","timestamp":1788998163628,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,25]]},"DOI":"10.7759\/cureus.25340","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T03:49:02Z","timestamp":1653536942000},"source":"Crossref","is-referenced-by-count":4,"title":["Spironolactone Versus Oral Contraceptive Pills in the Treatment of Adolescent Polycystic Ovarian Syndrome: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shriya","family":"Rajashekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganya","family":"Giri Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Kakarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Ausaja Gambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Yousri Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Haidar Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Tavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pulkita","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaza A","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale HF","year":"2018","unstructured":"Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018, 14:270-84. 10.1038\/nrendo.2018.24","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz R","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, et al.. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006, 91:4237-45. 10.1210\/jc.2006-0178","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","article-title":"Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches","volume":"38","author":"Ndefo UA","year":"2013","unstructured":"Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013, 38:336-55.","journal-title":"P T"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag G","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016, 31:2841-55. 10.1093\/humrep\/dew218","journal-title":"Hum Reprod"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-011-0130-0","article-title":"Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease","volume":"13","author":"McGowan MP","year":"2011","unstructured":"McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. 2011, 13:289-301. 10.1007\/s11936-011-0130-0","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01516-x","article-title":"Adolescent polycystic ovary syndrome according to the international evidence-based guideline","volume":"18","author":"Pe\u00f1a AS","year":"2020","unstructured":"Pe\u00f1a AS, Witchel SF, Hoeger KM, et al.. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020, 18:72. 10.1186\/s12916-020-01516-x","journal-title":"BMC Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01008.x","article-title":"PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors","volume":"113","author":"Broekmans FJ","year":"2006","unstructured":"Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006, 113:1210-7. 10.1111\/j.1471-0528.2006.01008.x","journal-title":"BJOG"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0957-5847(03)00050-7","article-title":"Recent developments in polycystic ovary syndrome","volume":"13","author":"Sharma A","year":"2003","unstructured":"Sharma A, Atiomo W. Recent developments in polycystic ovary syndrome. Curr Obstet Gynecol Rep. 2003, 13:281-286. 10.1016\/S0957-5847(03)00050-7","journal-title":"Curr Obstet Gynecol Rep"},{"key":"ref9","article-title":"Long term health consequences of polycystic ovarian syndrome: a review analysis","volume":"13","author":"Daniilidis A","year":"2009","unstructured":"Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009, 13:90-2.","journal-title":"Hippokratia"},{"key":"ref10","article-title":"Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese\/overweight PCOS women under hypocaloric diet","volume":"15","author":"Amiri M","year":"2014","unstructured":"Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, Ghofrani F, Bijani A, Ghorbani L, Delavar MA. Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese\/overweight PCOS women under hypocaloric diet. J Reprod Infertil. 2014, 15:205-13.","journal-title":"J Reprod Infertil"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","volume":"91","author":"Gambineri A","year":"2006","unstructured":"Gambineri A, Patton L, Vaccina A, et al.. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006, 91:3970-80. 10.1210\/jc.2005-2250","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study","volume":"89","author":"Ganie MA","year":"2004","unstructured":"Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004, 89:2756-62. 10.1210\/jc.2003-031780","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.02.118","article-title":"Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women","volume":"82","author":"Tartagni M","year":"2004","unstructured":"Tartagni M, Schonauer MM, Cicinelli E, Petruzzelli F, De Pergola G, De Salvia MA, Loverro G. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril. 2004, 82:752-5. 10.1016\/j.fertnstert.2004.02.118","journal-title":"Fertil Steril"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1410361","article-title":"Comparison of finasteride versus flutamide in the treatment of hirsutism","volume":"141","author":"Falsetti L","year":"1999","unstructured":"Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol. 1999, 141:361-7. 10.1530\/eje.0.1410361","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/jhrs.JHRS_72_18","article-title":"Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India","volume":"11","author":"Shah D","year":"2018","unstructured":"Shah D, Patil M. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. J Hum Reprod Sci. 2018, 11:96-118. 10.4103\/jhrs.JHRS_72_18","journal-title":"J Hum Reprod Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/tog.12345","article-title":"Polycystic ovary syndrome (PCOS)","volume":"19","author":"Balen AH","year":"2017","unstructured":"Balen AH. Polycystic ovary syndrome (PCOS). Obstet. Gynecol. 2017, 19:119-129. 10.1111\/tog.12345","journal-title":"Obstet. Gynecol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345529","article-title":"Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile","volume":"28","author":"Zulian E","year":"2005","unstructured":"Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005, 28:49-53. 10.1007\/BF03345529","journal-title":"J Endocrinol Invest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2017.09.11","article-title":"Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies","volume":"6","author":"Kamboj MK","year":"2017","unstructured":"Kamboj MK, Bonny AE. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. Transl Pediatr. 2017, 6:248-55. 10.21037\/tp.2017.09.11","journal-title":"Transl Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c927","article-title":"Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study","volume":"340","author":"Hannaford PC","year":"2010","unstructured":"Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010, 340:c927. 10.1136\/bmj.c927","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(18)30022-1","article-title":"The age of adolescence","volume":"2","author":"Sawyer SM","year":"2018","unstructured":"Sawyer SM, Azzopardi PS, Wickremarathne D, Patton GC. The age of adolescence. Lancet Child Adolesc Health. 2018, 2:223-228. 10.1016\/s2352-4642(18)30022-1","journal-title":"Lancet Child Adolesc Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","unstructured":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81.19-25. 10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil Steril"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz R","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, et al.. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009, 91:456-88. 10.1016\/j.fertnstert.2008.06.035","journal-title":"Fertil Steril"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.04.010","article-title":"Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women","volume":"86","author":"Hall KS","year":"2012","unstructured":"Hall KS, White KO, Rickert VI, Reame N, Westhoff C. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. Contraception. 2012, 86:518-25. 10.1016\/j.contraception.2012.04.010","journal-title":"Contraception"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2374","article-title":"Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis","volume":"98","author":"Domecq JP","year":"2013","unstructured":"Domecq JP, Prutsky G, Mullan RJ, et al.. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013, 98:4646-54. 10.1210\/jc.2013-2374","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0516","article-title":"Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial","volume":"177","author":"Alpa\u00f1\u00e9s M","year":"2017","unstructured":"Alpa\u00f1\u00e9s M, \u00c1lvarez-Blasco F, Fern\u00e1ndez-Dur\u00e1n E, Luque-Ram\u00edrez M, Escobar-Morreale HF. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. Eur J Endocrinol. 2017, 177:399-408. 10.1530\/EJE-17-0516","journal-title":"Eur J Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13042","article-title":"Association between duration of oral contraceptive use and risk of hypertension: a meta-analysis","volume":"19","author":"Liu H","year":"2017","unstructured":"Liu H, Yao J, Wang W, Zhang D. Association between duration of oral contraceptive use and risk of hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2017, 19:1032-41. 10.1111\/jch.13042","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4192940","article-title":"Low-dose spironolactone-pioglitazone-metformin normalizes circulating fetuin-a concentrations in adolescent girls with polycystic ovary syndrome","volume":"2018","author":"D\u00edaz M","year":"2018","unstructured":"D\u00edaz M, Gallego-Escuredo JM, L\u00f3pez-Bermejo A, de Zegher F, Villarroya F, Ib\u00e1\u00f1ez L. Low-dose spironolactone-pioglitazone-metformin normalizes circulating fetuin-a concentrations in adolescent girls with polycystic ovary syndrome. Int J Endocrinol. 2018, 2018:4192940. 10.1155\/2018\/4192940","journal-title":"Int J Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818805674","article-title":"Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome","volume":"10","author":"Alalami H","year":"2018","unstructured":"Alalami H, Sathyapalan T, Atkin SL. Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2018, 10:2042018818805674. 10.1177\/2042018818805674","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-020-00919-5","article-title":"Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials","volume":"20","author":"Almalki HH","year":"2020","unstructured":"Almalki HH, Alshibani TM, Alhifany AA, Almohammed OA. Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials. BMC Womens Health. 2020, 20:68. 10.1186\/s12905-020-00919-5","journal-title":"BMC Womens Health"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa032","article-title":"Toward a treatment normalizing ovulation rate in adolescent girls with polycystic ovary syndrome","volume":"4","author":"Ib\u00e1\u00f1ez L","year":"2020","unstructured":"Ib\u00e1\u00f1ez L, D\u00edaz M, Garc\u00eda-Beltr\u00e1n C, Malpique R, Garde E, L\u00f3pez-Bermejo A, de Zegher F. Toward a treatment normalizing ovulation rate in adolescent girls with polycystic ovary syndrome. J Endocr Soc. 2020, 4:bvaa032. 10.1210\/jendso\/bvaa032","journal-title":"J Endocr Soc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa155","article-title":"Efficacy of treatments for polycystic ovarian syndrome management in adolescents","volume":"5","author":"Al Khalifah RA","year":"2021","unstructured":"Al Khalifah RA, Florez ID, Zoratti MJ, Dennis B, Thabane L, Bassilious E. Efficacy of treatments for polycystic ovarian syndrome management in adolescents. J Endocr Soc. 2021, 5:bvaa155. 10.1210\/jendso\/bvaa155","journal-title":"J Endocr Soc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4089","article-title":"Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis","volume":"137","author":"Al Khalifah RA","year":"2016","unstructured":"Al Khalifah RA, Florez ID, Dennis B, Thabane L, Bassilious E. Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis. Pediatrics. 2016, 137:10.1542\/peds.2015-4089","journal-title":"Pediatrics"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.04.06.dc05-1938","article-title":"Alpha2-Heremans-Schmid glycoprotein\/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans","volume":"29","author":"Stefan N","year":"2006","unstructured":"Stefan N, Hennige AM, Staiger H, et al.. Alpha2-Heremans-Schmid glycoprotein\/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006, 29:853-7. 10.2337\/diacare.29.04.06.dc05-1938","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.588723","article-title":"Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study","volume":"113","author":"Ix JH","year":"2006","unstructured":"Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006, 113:1760-7. 10.1161\/CIRCULATIONAHA.105.588723","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-016-0171-y","article-title":"Plasma fetuin-A\/\u03b12-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes","volume":"17","author":"Sindhu S","year":"2016","unstructured":"Sindhu S, Akhter N, Shenouda S, Wilson A, Ahmad R. Plasma fetuin-A\/\u03b12-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes. BMC Immunol. 2016, 17:33. 10.1186\/s12865-016-0171-y","journal-title":"BMC Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard \u00d8","year":"2012","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012, 366:2257-66. 10.1056\/NEJMoa1111840","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren JM","year":"2001","unstructured":"Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001, 323:131-4. 10.1136\/bmj.323.7305.131","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno W","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008, 117:93-102. 10.1161\/CIRCULATIONAHA.107.709204","journal-title":"Circulation"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.027","article-title":"Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits","volume":"106","author":"Dokras A","year":"2016","unstructured":"Dokras A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits. Fertil Steril. 2016, 106:1572-9. 10.1016\/j.fertnstert.2016.10.027","journal-title":"Fertil Steril"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand IS","year":"2017","unstructured":"Anand IS, Claggett B, Liu J, et al.. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail. 2017, 5:241-52. 10.1016\/j.jchf.2016.11.015","journal-title":"JACC Heart Fail"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.120677","article-title":"Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis","volume":"185","author":"Bird ST","year":"2013","unstructured":"Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013, 185:E115-20. 10.1503\/cmaj.120677","journal-title":"CMAJ"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0755","article-title":"Mechanisms in endocrinology: recent advances in cardiovascular aspects of polycystic ovary syndrome","volume":"166","author":"Sathyapalan T","year":"2012","unstructured":"Sathyapalan T, Atkin SL. Mechanisms in endocrinology: recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol. 2012, 166:575-83. 10.1530\/EJE-11-0755","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89607-spironolactone-versus-oral-contraceptive-pills-in-the-treatment-of-adolescent-polycystic-ovarian-syndrome-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:18Z","timestamp":1707507378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89607-spironolactone-versus-oral-contraceptive-pills-in-the-treatment-of-adolescent-polycystic-ovarian-syndrome-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.25340","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}